Home/Pipeline/Oral Insulin

Oral Insulin

Diabetes

Phase 3Active

Key Facts

Indication

Diabetes

Phase

Phase 3

Status

Active

Company

About Premas Biotech

Premas Biotech fast‑tracks biologics and vaccine development with patented platforms and end‑to‑end services.

View full company profile

Therapeutic Areas

Oncology Immunology Infectious Diseases Metabolic

Other Diabetes Drugs

Drug	Company	Phase	Status
AdOral® Insulin	Adocia	Preclinical	Platform Development
PRX-3140	Nanopharmaceutics	Clinical	Active
Insulin Program	Biolingus	Pre-clinical	Active
Insulin Aspart Biosimilar	Meitheal Pharmaceuticals	Preclinical	Active
Insulin Glargine Biosimilar	Meitheal Pharmaceuticals	Preclinical	Active
Insulin Lispro Biosimilar	Meitheal Pharmaceuticals	Preclinical	Active
Liraglutide Injection	Meitheal Pharmaceuticals	Approved	Active
Diabetes Clinical Trials	DM Clinical Research	Not Specified	Active
Diabetes Therapeutic	Housey Pharmaceutical Research Laboratories	Not specified	Active
Diabetes Research	Evidation Health	Research	Active
Injectable HDV-Rapid Acting Insulin (Open Label, MoA)	Diasome Pharmaceuticals	Phase 2	Active
Glucose-Responsive Insulin Receptor Agonist	Protomer Technologies	Pre-clinical (integrated into Lilly pipeline)	Active